A Shatavari supplement for menopausal symptoms in post-menopausal women

You may qualify if

• Female subjects aged 45-60 years at screening.
• Post-menopausal status, defined as no menstrual period for at least 12 months, graded as post-menopausal per STRAW classification (not due to pregnancy, lactation, or medical/surgical causes).
• Menopause Rating Scale (MRS) score > 9 at screening.
• Average frequency of hot flashes >= 3 per day for at least 7 consecutive days prior to screening.
• Willing and able to provide written informed consent and comply with study procedures, including maintaining the daily hot-flash diary.

You can't join if

• Body mass index (BMI) <= 18 kg/m2 or > 35 kg/m2.
• History of endometrial hyperplasia, endometrial cancer, cervical cancer, breast cancer, or other sex hormone-related cancers.
• History of uterine resection or hysterectomy.
• Unexplained abnormal uterine bleeding occurring after >= 1 year of menopause.
• History of severe migraine, or diagnosis of thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or history of coronary angioplasty within 1 year prior to screening.
• Currently undergoing treatment for severe disease of the cardiovascular, immune, respiratory, gastrointestinal/hepatobiliary, renal/urologic, nervous, or musculoskeletal system, or for infectious disease or malignancy.
• Psychiatric disorders: clinically diagnosed depression, anxiety disorder, or sleep disorder within 3 months prior to screening treated with medication, or current use of neuropsychiatric drugs.
• Use of thyroid hormones, clonidine, anticoagulants, antiplatelet agents (e.g., warfarin, clopidogrel), or osteoporosis treatments within 3 months prior to screening.
• Use of any medication or plant-based hormone-like extract for menopausal symptoms within 3 months prior to screening.
• Continuous intake of health functional foods related to menopause or herbal medicine within 1 month prior to screening.
• Uncontrolled hypertension (resting blood pressure >= 160/100 mmHg after 10 minutes of rest).
• Uncontrolled diabetes (fasting blood glucose >= 180 mg/dL or HbA1c > 9.5%).
• Excessive use of tobacco (>20 cigarettes/day), caffeine (>5 cups/day), or alcohol (>14 drinks/week) within 4 weeks prior to screening.
• History of clinically reported drug abuse within 1 year prior to screening.
• Known clinically significant hypersensitivity to any component or excipient of the investigational product.
• Participation in another interventional clinical trial within 1 month prior to study start.
• Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation.